Veronique Ehrhard
Chief Financial Officer Pharma Healthtech
France
Indicative price: € 1500 - 1625 / day
Veronique Ehrhard
Premium Expert
Chief Financial Officer Pharma Healthtech
France
Specialist of the finance function on transformation issues: fund raising, international deployment, disposals, acquisitions, restructuring, development plan, product valuation, in & out licensing, R&D portfolio optimization, structuring of the finance function. (process tools teams)
Availabilities
Veronique is available from the 24-08-2020
Veronique is available for missions Full time, Time sharing, Special mission
Veronique moves to the Regional level
The expert in a few words....
HEC. CEDEP INSEAD. Transition manager since 2019 after 25 years of experience in France and US within international pharmaceutical groups (health, pharma, biotech, healthtech) GALDERMA -NESTLE SKIN HEALTH, HRA PHARMA, LEO PHARMA, METABIOLAB
His specific skills
- Accompanying growth through Business Development: as CFO of Galderma's BD (€1M turnover), I set up the valuation aspect of acquisitions (7 acquisitions in 3 years) and I modelled the internal R&D portfolio (basis for management decisions).
- Accompanying growth through financing: at HRA (EU group €50m turnover), I managed a fundraising campaign from A to Z: business plan, valuation, pitchs, data room, due diligence: €25m raised for €50m turnover.
- Accompanying the transformation and cultural change: at Leo Pharma as Dir Fin, I accompanied the restructuring of the French subsidiary (€450M ca -600 people) with an EPS allowing the launch of a new BU financed by the human commercial disinvestment with the target of general practitioners.
- Accompanying the transformation of the Finance function: at HRA, as Group CFO, I structured the consolidation and set up a process and a budgeting tool in 12 months.
- Leading international multicultural cross-functional projects: at Leo Pharma I managed the "innohep" project: in 3 months I aligned the international commercial, industrial and production teams and we produced a common recommendation approved by the group CODIR.
- Financial Director specialising in the Pharma and Biotechs sector in France: pharma taxation (transfer prices, pharma tax), distribution (wholesalers, pharmacies, EEC), management of intangibles, sales prices ...
His experience
Veronique has 35 years of experience
Industrie pharmaceutique
May 2012 - August 2012
2012 -2016 Secretary General France Reporting to the CEO France Member CODIR.
Leo Pharma
Voisins le B - France
Manage a tax audit in a transfer pricing context - limit adjustment Steering of international cross-functional projects: Director of the corporate project "innohep": in 3 months, alignment of the industrial and marketing teams and production of a joint recommendation approved by the CODIR Group Implement SAP for the industrial and commercial activity and drive the change for internal customers. Closing 2015 approved, 30% reduction in headcount counted implementation of integrated processes (e.g. Purchasing) Manage a tax audit in a transfer pricing context - limited recovery
Industrie pharmaceutique
May 2012 - August 2012
2017 2018 CFO France Canada Benelux - reporting to EU CFO - Member CODIR
Leo Pharma
Voisins le B - France
Deploy SAP: Outsource transactional accounting to India, Restructure Business France (plan, PSE, new BU launch), Distribution: Wholesaler relations and product allocation management
Industrie pharmaceutique
June 2010 - November 2010
Group CFO - Reporting to the CEO
HRA Pharma
Paris - France
Raising 25M funds for a group with 50M in sales Overhaul the management information system: Hyperion Planning implemented in 6 months Optimize the portfolio: Acquisition of T of a Novartis product
Industrie pharmaceutique
January 2006 - February 2006
2006 2009 Chief Financial Officer Business Development - Deputy CFO Group
Nestlé Skin Health (ex Lab Galderma)
La Defense - France
Acquire new products: valuation (models, data collection scenarios for value sharing) and negotiations with third parties (USn France): 7 contracts signed Define the strategic choices: 10-year business plan recommendation to create the Aesthetics BU approved by the shareholders Optimize the R&D portfolio: modeling and valuation of internal research projects for optimal management of resources
Industrie pharmaceutique
January 2003
Group Controlling Director reporting to the Group CFO
Nestlé Skin Health (Ex Lab Galderma)
La Defense - France
Significant improvement in the relevance of the management tools contributing to the Group's objectives being exceeded: +2 points in margin over the period despite a 15% fall in the dollar (60% of sales).
Industrie pharmaceutique
January 2002
Finance Director Zone Europe Middle-East Africa Australia reporting to VP Zone
Nestle Skin Health (ex Lab Galderma)
La Defense - France
Managing the results of the 152M€ Zone 11 Countries 10% growth = objectives achieved
Industrie pharmaceutique
February 1999 - July 1999
Controller then Financial Director US subsidiary
Neslte Skin Health (ex Lab Galderma)
Dallas - United States
Financial management of a subsidiary representing 60% of the group's sales 10% growth 400m dollars - in a radically different cultural context
His education
- 2020 : AQI Administrateur indépendant
- 2000 : Insead- Cedep GMP
- 1982 : HEC
Its missions
- At LEO Pharma in 2017, I co-piloted the restructuring of the French business (€200m): 10-year modelling, recommendations, EPS support (valuation, negotiation support) and change management for the teams, resulting in the creation of a biological BU financed by commercial disinvestment from the MGs.
- At Leo Pharma, France from 2015 to 2018, I accompanied the accelerated transformation of the subsidiary: from a decentralized country management to a centralized (regional) management, from a direct hierarchy to a matrix structure, from a local (French) culture to a group (Danish) culture, from a statutory financial vision to a BU-based management based on the implementation of SAP.
- At LEO Pharma in 2016 I led the group project "innohep" aiming at defining the future geographical presence of this key product. In three months, in a tense multi-cultural context, I aligned the sales and industrial teams on a common vision and we produced a recommendation that was approved by the group CODIR.
- At HRA, a European group, I raised funds from A to Z in 2011: valuation business plan, negotiations with the bank, pitching, setting up the data room, due diligence: €25m raised for €50m in turnover.
- At Galderma from 2006 to 2009 I was Chief Financial Officer of Business Development. I have modelled and valued the R&D portfolio for prioritisation purposes.E,n 3 years, I have valued and co-negotiated 7 licensing-in contracts, including the EU licence for Ipsen's "Botox".
Languages (2)
- Anglais : courant
- Allemand : intermediaire
Skills (5)
- R&D valorization
- Financial steering ww: planning, execution, monitoring
- Change management for multicultural teams
- Fund raising from business plan to closing
- R&D development, licensing in & out
Activity areas (6)
- Biotechnology
- Think Tanks
- Pharmaceuticals
- Veterinary
- Medical Devices
- Research
Types of business (5)
- Start-up
- Subsidiaries of foreign groups
- Investment funds and holding companies
- Groups and large companies
- Small and medium-sized enterprises